Roche CEO Hopes For Progress As China Tackles Approval Lag
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent signs that China is aiming to speed up its lengthy drug review processes are “encouraging” but there is still more to be done towards implementing “good and robust regulatory science” in the country, says Roche CEO Severin Schwan.